Kineta Profit Margin 2014-2024 | KANT
Current and historical gross margin, operating margin and net profit margin for Kineta (KANT) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Kineta net profit margin as of June 30, 2024 is 0%.
| Kineta Annual Profit Margins |
| Kineta Quarterly Profit Margins |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
|
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|
